What is the role of selective estrogen receptor modulators (SERMs) in the treatment of osteoporosis?

Updated: Sep 26, 2019
  • Author: Monique Bethel, MD; Chief Editor: Herbert S Diamond, MD  more...
  • Print

SERMs are considered to provide the beneficial effects of estrogen without the potentially adverse outcomes. Raloxifene (Evista) is a SERM indicated for the treatment and prevention of osteoporosis in postmenopausal women. The usual dose is 60 mg given orally daily. It can also be given in combination with calcium and vitamin D. It is the first SERM studied for breast cancer prevention, and it decreases bone resorption through actions on estrogen receptors.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!